TG Therapeutics, Inc. (TGTX)
TGTX moved a median of -0.06% 30 minutes after news, and +0.12% by the close. How TGTX actually reacts to news — the realized, point-in-time move the market made, measured across 220 labeled events over the last three years with zero look-ahead.
TGTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.02% | 51% | 220 |
| 30-min | -0.06% | 47% | 220 |
| 60-min | +0.07% | 51% | 220 |
| to close | +0.12% | 52% | 219 |
| Middle 50% of TGTX reactions | -1.30% to +1.03% |
|---|---|
| Median reaction (30-min) | -0.06% |
| Measured reactions | 220 |
Half of all TG Therapeutics, Inc. news events land between -1.30% and +1.03% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TGTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | +0.23% | 58% | +0.74% |
| Analyst downgrades | 10 | +0.98% | 70% | +0.47% |
| Rating reiterations | 55 | +0.18% | 60% | 0.00% |
| Price-target raises | 16 | +0.24% | 56% | -0.66% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how TGTX ranks against every other measured name →
That’s how TGTX usually reacts — get an email when it moves on news →Email me when TGTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TGTX's baseline. Nothing else.
Recent TGTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis | Press release | Business Wire | -0.39% | -0.20% | |
| TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 | Press release | Business Wire | -0.46% | +0.00% | |
| TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.04% | +1.90% | |
| TG Therapeutics to Participate in the Cantor Global Healthcare Conference | Press release | GlobeNewswire | +1.00% | -1.20% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.38% | -0.66% | |
| Form 8-K TG THERAPEUTICS, INC. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -2.94% | -9.33% | |
| TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance | Press release | GlobeNewswire | -2.94% | -9.33% | |
| TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | -0.35% | -2.53% | |
| TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia | Press release | GlobeNewswire | +4.43% | +4.48% | |
| Form 8-K TG THERAPEUTICS, INC. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -1.64% | +2.65% | |
| TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial | Press release | GlobeNewswire | +0.28% | +2.10% | |
| Form 8-K TG THERAPEUTICS, INC. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -1.53% | +3.99% | |
| TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy) | Press release | GlobeNewswire | -1.53% | +3.99% | |
| TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference | Press release | GlobeNewswire | +0.23% | -0.97% | |
| TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology | Press release | GlobeNewswire | -0.32% | -0.37% | |
| TG Therapeutics to Participate in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.05% | -0.46% | |
| Form 8-K TG THERAPEUTICS, INC. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +0.05% | -0.46% | |
| TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial | Press release | GlobeNewswire | -2.02% | -2.68% | |
| TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting | Press release | GlobeNewswire | -0.22% | +1.82% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.26% | +2.56% | |
| Form 8-K TG THERAPEUTICS, INC. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +6.17% | +15.78% | |
| TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance | Press release | GlobeNewswire | +6.17% | +15.78% | |
| Form DEF 14A TG THERAPEUTICS, INC. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | -0.65% | -0.03% | |
| TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update | Press release | GlobeNewswire | +0.27% | +0.60% | |
| TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting | Press release | GlobeNewswire | +0.19% | +5.02% | |
| TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI | Press release | GlobeNewswire | -0.09% | -0.46% | |
| Form 8-K TG THERAPEUTICS, INC. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | +0.73% | |
| TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million | Press release | GlobeNewswire | +1.98% | -0.78% | |
| Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis | Press release | GlobeNewswire | +0.34% | +0.31% | |
| TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting | Press release | GlobeNewswire | -0.26% | +2.70% | |
| Form 10-K TG THERAPEUTICS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.66% | +0.03% | |
| Form 8-K TG THERAPEUTICS, INC. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +5.32% | +8.84% | |
| TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Press release | GlobeNewswire | +5.32% | +8.84% | |
| TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update | Press release | GlobeNewswire | +1.59% | +3.24% | |
| Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis | Press release | GlobeNewswire | +1.16% | +2.22% | |
| TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis | Press release | GlobeNewswire | -0.83% | +2.81% | |
| TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum | Press release | GlobeNewswire | +0.35% | +2.16% | |
| TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum | Press release | GlobeNewswire | +1.50% | +0.65% | |
| Form 8-K TG THERAPEUTICS, INC. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | +5.49% | -5.20% | |
| TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones | Press release | GlobeNewswire | +5.49% | -5.20% | |
| TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.39% | +1.68% | |
| TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | -0.89% | -1.04% | |
| TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies | Press release | GlobeNewswire | -0.19% | -2.94% | |
| TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit | Press release | GlobeNewswire | +0.63% | +3.53% | |
| Form 10-Q TG THERAPEUTICS, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.38% | -1.98% | |
| Form 8-K TG THERAPEUTICS, INC. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -9.53% | -7.19% | |
| TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance | Press release | GlobeNewswire | -9.53% | -7.19% | |
| TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update | Press release | GlobeNewswire | +1.62% | +2.26% | |
| TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | Press release | GlobeNewswire | -0.55% | +2.25% | |
| New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment | Press release | GlobeNewswire | +0.39% | -0.53% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TGTX section they belong to.
Where else TGTX is measured.
TGTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
| PROVECTUS BIOPHARMS (PVCT) | 220 | +0.01% | 50% |
| Lipocine Inc. (LPCN) | 219 | +0.34% | 52% |
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is TG Therapeutics, Inc.'s median reaction calculated?
Every labeled TGTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 220 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of TGTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TGTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.